This week, there are two very interesting articles on the importance of folic acid supplementation during pregnancy. Not only does folic acid reduce the risk of neural tube defects, it may affect other aspects of [...]
This week we have several interesting and clinically relevant articles. We have long know that depression during pregnancy is one of the most robust predictors of postpartum depression; Lupattelli and colleagues demonstrate that treatment during [...]
Soon after the Center for Women’s Mental Health was established in 1989, we started receiving phone calls (followed by emails) from women and their treaters seeking information regarding the safest way to treat psychiatric disorders [...]
Each year in the United States, the menopause transition is experienced by 1.5 million women. With this change in the hormonal milieu comes troublesome symptoms, including vasomotor symptoms, decreased libido, insomnia, changes in mood, fatigue, [...]
Several recent articles indicate that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the [...]
In 2006, Chambers and colleagues published an article linking selective serotonin reuptake inhibitor (SSRI) antidepressant use during late pregnancy to an increased risk of persistent pulmonary hypertension in the newborn (PPHN). PPHN is a cardiovascular [...]
Studies evaluating the relationship of caffeine to vasomotor symptoms have yielded conflicting results.
Approximately 70% of all women experience hot flashes and/or night sweats (also called vasomotor symptoms or VMS) during the menopause transition. Although estrogen-containing hormone therapy is highly effective in managing these symptoms, various studies have raised concerns regarding the risks associated with prolonged use of hormone therapy and many women now use other non-hormonal options to manage their symptoms, including over-the-counter complementary and alternative medicines (CAMs), including soy isoflavones, black cohosh, and omega-3 fatty acids. However, the data regarding the effectiveness of these alternative treatments has been mixed.
While there are concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain settings. A study presented this week at the Endocrine Society’s annual meeting which analyzed data from 43 randomized clinical trials suggests that menopausal hormone-replacement therapy does not appear to affect mortality either positively or negatively.
Up to 80% of women experience vasomotor symptoms (VMS) as they transition into the menopause phase. While clinical guidelines suggest that VMS typically last from 6 months to 2 years, we often see women with VMS lasting for a much longer period of time. To more accurately assess the duration of VMS in perimenopausal women, researchers analyzed data from 1449 women included in the Study of Women's Health Across the Nation (SWAN), an observational study of women entering menopause. Here is a summary of the key findings: